Please assess the completion status of the following clinical trial:

Trial Title: ASCT for Relapsed APL After Molecular Remission

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Men or women between age 18-60 years old~* Acute promyelocytic leukemia after relapse with confirmed cytogenetics t(15;17) and molecular analysis (PML-RARalpha)~* Mobilized peripheral CD34+ over 2x106/kg with negative PML-RAR alpha confirmed by PCR~* European Cooperative Oncology Group performance status 0-3~* Serum bilirubin \< 1.5x the upper limit of normal (ULN)~* Serum alanine transaminase (ALT)/aspartate transaminase values \< 2.5 x ULN~* Subjects (or their legally acceptable representatives) must signed an informed consent document indicating that they understanding the purpose of and procedures required for the study and are willing to participate in the study~Exclusion Criteria:~* Woman of child bearing potential~* Serum creatinine \> 400 Micromol/l after initial resuscitation patients with previous Grade 2-4 peripheral neuropathy~* Uncontrolled diabetes (if receiving antidiabetic agents, subjects must be on a stable dose for at least 3 months before first dose of study drug)~* Uncontrolled or severe cardiovascular disease including myocardial infarction within 6 months of enrollment, uncontrolled angina, clinically significant pericardial disease, or III-IV heart failure~* Known allergy to idarubicin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- ASCT in relapsed APL (Type: EXPERIMENTAL): autologous hematopoietic cell transplantation for patients with relapsed APL after achieving molecular remission

Based on this trial design, predict the completion outcome and termination type (if applicable).